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ing, right lower quadrant abdominal pain radiating to her right ﬂank,
and nausea without emesis. She also reported severe headache with
aura and photophobia, lightheadedness, and blurry vision, as well as
generalized malaise and urinary incontinence over the preceding 2–
3 weeks.Keywords:
Ovarian clear cell carcinoma
Non-bacterial thrombotic endocarditis
Hypercoaguability of malignancy13.7 g/dL, hematocrit of 42.2% and platelet count of 225,000/uL.1. Introduction
Systemic hypercoagulability is a complication of malignancy, with
up to 10% of ovarian cancer patients developing venous thromboembo-
lism (VTE) (Abu Saadeh et al., 2013). In cancer patients, the presence of
deep vein thrombosis (DVT) or pulmonary embolism (PE) is associated
with increased risk of readmission and death (Levitan et al., 1999). Ad-
ditionally, non-cancer patients presenting with VTE are ﬁve times as
likely to be subsequently diagnosed with cancer (Baron et al., 1998).
The hypercoagulable state of malignancy is related to a combination of
procoagulant factor expression, cytokine secretion, alterations to the
endothelium, and consequences of treatment (e.g. immobilization, sur-
gery, chemotherapy) (Falanga et al., 2013).
Although the most common complication from cancer-related hy-
percoagulability is VTE, the risk extends to arterial thromboses (el-
Shami et al., 2007). Non-Bacterial Thrombotic Endocarditis (NBTE) is a
conditionwhereby, in absence of infection, thrombi of platelets and ﬁbrin
are deposited on cardiac valves, with potential for systemic embolization.2. Case
A 61 year-old woman with a known 4.1 cm ascending aortic aneu-
rysm, aortic valve regurgitation, and migraine headache with auraof Medicine, Department of
Cedar Street, PO Box 208063;
s.
ight).
. This is an open access article underOn presentation, she was afebrile with a blood pressure of 117/61,
pulse of 79, respiratory rate of 16, and oxygen saturation of 99% on room
air. Physical examination revealed right-sided lower abdominal tender-
ness. A CT scan demonstrated a 12 cm complex cystic pelvic mass, splenic
and renal infarcts, and ascites. Initial labs revealedWBC 12,800/uL, Hgb of
On hospital day 1, the abdominal pain improved, however, she re-
ported left substernal chest pain. An electrocardiogram revealed a
non-ST elevated myocardial infarction (NSTEMI) with elevated tropo-
nins, peaking at 1.67 ng/mL. A transthoracic echocardiogram revealed
a stable dilated ascending aortic aneurysm and severe aortic regurgita-
tion, with preserved ejection fraction of 65%. A CT scan of the head
showed focal areas of hypoattenuation concerning for underlying ische-
mic infarcts, though neurological exam remained non-focal. Tumor
markers were notable for elevated serum CA125 to 69 U/mL, serum
CA19-9 elevated to 284 U/mL, and normal CEA of 1.7 ng/mL. The
patient's platelet count dropped to 109,000/uL.
On hospital day 2, the patient complained of shortness of breath
with pleuritic chest pain. A thoracic CT angiogram revealed bilateral
segmental and subsegmental PEs. She was started on therapeutic
heparinization. The patient's platelet count dropped to 47,000/uL. A
heparin-induced thrombocytopenia (HIT) panel was negative. On hos-
pital day 3 the patient reported transient visual ﬁeld deﬁcits, and right
upper extremity weakness; CT and MRI of the brain revealed multiple,
scattered acute and subacute ischemic infarcts as well as foci of sub-
arachnoid hemorrhage. The heparin drip was discontinued and the pa-
tient underwent IVC ﬁlter placement.
On hospital day 4, the patient developed word ﬁnding difﬁculties,
right upper extremity weakness. Worsening ischemia and subarach-
noid hemorrhages were seen on a repeat brain MRI. Coagulation
studies revealed platelets of 37,000/uL, INR of 1.13, and PTT of
35.2 s. An infusion of 1 pack of platelets did not yield an appropriate
rise. In the context of multiple embolic infarcts, the thrombophilia
was thought to be consumptive in etiology. There was a high suspi-
cion for NBTE.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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sions were held. She was a poor candidate for aortic valve replacement,
as she would be unable to be anticoagulated during the procedure due
to intracranial hemorrhages. The decision was made to remove the
ovarian mass in hopes of reversing the coagulopathy.
The next morning, on hospital day 5, her platelets were 36,000/uL,
improving to 86,000/uL with an infusion of 1 pack of platelets. She
underwent an exploratory laparotomy, bilateral salpingo-oophorecto-
my, and an omental biopsy with an estimated blood loss of 100 mL.
An intraoperative transesophageal echocardiogram revealed vegeta-
tions on all three aortic valve leaﬂets consistentwithNBTE. She received
two additional units of platelets during surgery with improvement to
124,000/uL post-operatively. A frozen section of the ovarian mass was
consistent with a clear cell adenocarcinoma of the ovary. Given the
thrombophilia, additional staging was not performed. After the proce-
dure she remained intubated and was sent to the Surgical Intensive
Care Unit.
On postoperative day 1 shewas extubated and found to have exten-
sive bilateral DVT, further evolution of ischemic infarcts, and a new
7 mm cerebellar parenchymal hemorrhage. After reaching a nadir he-
matocrit of 20.1%, she was transfused 2 units of packed RBCwith recov-
ery to 24.8%. Over the next two days, her hematocrit recovered to 28.5%,
her platelets stabilized at 168,000/uL, and repeat CT showed no further
embolic or hemorrhagic events. However, her respiratory status wors-
ened despite diuresis and she was re-intubated on postoperative day
3. She developed supraventricular tachycardia and was started on an
amiodarone drip. An echocardiogram demonstrated a decrease in her
ejection fraction from 65% to 28%.
She then began a slow and steady cardio-pulmonary, hematologic,
and neurologic recovery. She was extubated on postoperative day 7,
restarted on a heparin drip on postoperative day 13, and transitioned
to enoxaparin injections two days later. On postoperative day 17, she
was discharged home in good condition. Final pathology showed FIGO
Stage IA ovarian clear cell carcinoma. One week after discharge she
was started on adjuvant carboplatin and paclitaxel.
After 6 cycles of carboplatin and paclitaxel her CA-125 level had de-
creased to 7 U/mL, her follow-up echocardiogram revealed an ejection
fraction of 55%, and a CT scan of her abdomen and pelvis showed no ev-
idence of disease. She then underwent a completion of staging (hyster-
ectomy, pelvic and para-aortic lymph nodes, omentectomy, and
directed biopsies), which revealed no evidence of disease on ﬁnal pa-
thology. She remains with no evidence of disease 9 months from her
original diagnosis.
3. Discussion
We present an unusual case of a patient with an ovarian clear cell
carcinoma, presenting with systemic vascular dysfunction in the form
of DVT, PE, ischemic and hemorrhagic stroke, and myocardial, renal,
and splenic infarcts, all in the context of NBTE and consumptive and
non-infectious DIC.
The differential diagnosis of acute, widespread arterial infarction in-
cludes: VTE through a patent foramen ovale, cardiac thrombus secondary
to arrhythmia or malfunction, plaque embolization in atherosclerosis,
endocarditis, and various hypercoagulable states including DIC, anti-
phospholipid syndrome, and HIT. Although rare, NBTE should be consid-
ered early in a patient with manifestations of arterial infarction such as
stroke, myocardial infarction, or hematuria. In our patient, transthoracic
echocardiogram found no evidence of a patent foramen or mural throm-
bus. She remained afebrile with negative cultures and a mildWBC eleva-
tion, so suspicion for infectious endocarditis or DIC was low, and the
coagulopathy preceded the introduction of heparin. Considering the
patient's known aortic root aneurysm, clinical suspicion centered on
NBTE.
NBTE has no ofﬁcial diagnostic criteria, and refers to valvular lesions
of varying underlying etiology, in the absence of systemic infection. Theincidence of NBTE at autopsy ranges from 0.9–2.3%, with over 60% of
cases associated with underlying malignancy (Deppisch & Fayemi,
1976; Rosen & Armstrong, 1973). Coexisting coagulation abnormalities
including thrombocytopenia, prolongation of PT, and depression of ﬁbrin-
ogen are common (Rosen&Armstrong, 1973). Arterial thromboembolism
is the primary health risk from NBTE and occurs in about 50% of patients
(el-Shami et al., 2007). The most common neoplasms associated with
NBTE are pancreatic, lung, and stomach cancers, with the strongest histo-
logical association being adenocarcinoma (Deppisch & Fayemi, 1976;
Rosen & Armstrong, 1973). Mucin secreted by tumor cells has been spec-
ulated to play a role in development of NBTE in some cases (Min et al.,
1980).
Recommendations for treatment of malignancy associated NBTE
include therapeutic anticoagulation with heparin, and treatment of
the underlying malignancy. Warfarin has been found to be ineffective
at preventing recurrent thromboembolic events in NBTE (el-Shami et
al., 2007), while factor Xa and thrombin inhibitors remain largely un-
studied. Valvular surgery is only indicated in cases with concomitant
heart failure. In the setting of worsening DIC, we proceeded with surgi-
cal removal of the ovarian mass.
In a study of the Medicare population, ovarian cancer patients
showed the highest rate of malignancy-associated DVT or PE (Levitan
et al., 1999). Ovarian clear cell carcinoma has an incidence of VTE rang-
ing from 27–42%, with odds ratio of 2.5–5.2 relative to other epithelial
ovarian cancers (Duska et al., 2010; Matsuura et al., 2007). NBTE has
been described previously in association withmultiple gynecologic ma-
lignancies (Delgado & Smith, 1975), butmost oftenwith ovarian cancer.
Of four cases ofNBTE identiﬁed in associationwith ovarian clear cell car-
cinoma, two presented during metastatic recurrence (Devulapalli et al.,
2012; Yilmaz et al., 2015), and two during primary presentation of the
malignancy (Oueida & Scola, 2011; Aryana et al., 2006).
In conclusion, we present a rare case of coagulopathy and NBTE as
the primary presentation of early stage ovarian clear cell carcinoma.
NBTE is a rare paraneoplastic syndrome associated with a wide variety
of malignancies and often presents with systemic emboli. We demon-
strated that the otherwise refractory coagulopathy can be reversed by
surgical removal of the mass.
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